Delivery Order SPE2DB24D3013-SPE2DB26FFFQV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,036.57 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on August 26, 2025, with an ultimate completion date of August 27, 2025, and represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the delivery order from its Conshohocken facility. This...
- The Defense Logistics Agency awarded a delivery order valued at $14,768.24 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count) under a firm fixed-price contract type. The award was made on September 17, 2025, with an ultimate completion date of September 18, 2025. This non-set-aside award represents a competitive procurement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Rexulti 2 mg tablets (quantity: 30 units) with a ceiling value of $2,927.61. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,494.83 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count package), with a completion date of September 22, 2025. This is a firm fixed price delivery order issued under a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $33,529.43 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed price contract. The award, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This...
- The Defense Logistics Agency awarded a delivery order valued at $17,977.69 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (quantity: 30 count) under a firm fixed price contract. The award was made on August 20, 2025, with an ultimate completion date of August 21, 2025. This is a non-set-aside competitive award, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,417.22 to AmerisourceBergen Drug Corp for Rexulti 2 mg tablets (30-count package) on September 25, 2025, with an ultimate completion date of September 26, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $11,846.76 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed price contract. The award, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this pharmaceutical delivery order and functions as a...
- The Defense Logistics Agency awarded a delivery order valued at $3,499.29 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units). This competitive award, issued on June 18, 2025, with an ultimate completion date of June 20, 2025, carries a firm fixed price and no set-aside designation. The contract represents a child delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion global...
- The Defense Logistics Agency awarded a $10,676.55 delivery order to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 1 mg on September 5, 2025, with a completion date of September 8, 2025. This competitively awarded, firm fixed-price contract is non-set-aside and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where the vendor maintains its corporate...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB26FFFQVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,122.46 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed price contract. This non-set-aside award was issued on October 17, 2025, with an ultimate completion date of October 20, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the performer of record for this delivery order. This award represents a child contract action under the company's larger indefinite delivery contract with DLA Troop Support Medical. This delivery order falls under AmerisourceBergen's comprehensive Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The IDC serves as a global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates consistent capability to fulfill military and veteran healthcare pharmaceutical needs through competitively awarded contracts with the DLA Medical Supply Chain, covering diverse therapeutic domains including neurological treatments, pain management, and specialty medications.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 10/17/25 |